id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
cord-311099-59pnm4fn	Lubel, John S	Liver disease and the renin–angiotensin system: Recent discoveries and clinical implications	2008-06-28		.txt	text/plain	7737	285	37	A study in the isolated perfused rat liver Hemodynamic and antifibrotic effects of losartan in rats with liver fibrosis and/or portal hypertension Angiotensin converting enzyme inhibitors and angiotensin II antagonists as therapy in chronic liver disease Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis Chronic administration of losartan, an angiotensin II receptor antagonist, is not effective in reducing portal pressure in patients with preascitic cirrhosis Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension The levels of renin activity, angiotensin converting enzyme and angiotensin II in cirrhotic patients with ascites undergoing portacaval shunt Effects of captopril on renal function in patients with cirrhosis and ascites Acute effects of captopril on systemic and renal hemodynamics and on renal function in cirrhotic patients with ascites Clinical usefulness of the angiotensin II receptor antagonist losartan in patients with portal hypertensive gastropathy Effects of captopril on hepatic venous pressure and blood flow in patients with liver cirrhosis Captopril reduces portal pressure effectively in portal hypertensive patients with low portal venous velocity Haemodynamic effects of enalaprilat on portal hypertension in patients with HBsAg-positive cirrhosis Effect of enalapril treatment and sclerotherapy of esophageal varices on hepatic hemodynamics in portal hypertension Circulating activities of angiotensin-converting enzyme, its homolog, angiotensin-converting enzyme 2, and neprilysin in a family study A1166C angiotensin II type 1 receptor gene polymorphism may predict hemodynamic response to losartan in patients with cirrhosis and portal hypertension Significance of chymase-dependent angiotensin II formation in the progression of human liver fibrosis Hepatic chymase level in chronic hepatitis: colocalization of chymase with fibrosis Renin-angiotensin system inhibition: how much is too much of a good thing Endogenous angiotensin II levels and the mechanism of action of angiotensin-converting enzyme inhibitors and angiotensin receptor type 1 antagonists aldosterone and renal haemodynamics in cirrhosis with ascites Hepatic hemodynamics and the renin-angiotensin-aldosterone system in cirrhosis Diagnostic significance of serum angiotensin-converting enzyme activity in biochemical tests with special reference of chronic liver diseases Liver fibrosis: a balance of ACEs? The renin-angiotensin system in a rat model of hepatic fibrosis: evidence for a protective role of Angiotensin Metabolism of angiotensin-(1-7) by angiotensin-converting enzyme Converting enzyme determines plasma clearance of angiotensin-(1-7) Pathways for angiotensin-(1-7) metabolism in pulmonary and renal tissues Angiotensin 1-7 reduces bile duct proliferation and hepatic fibrosis in the bile duct ligated rat Angiotensin-converting enzyme 2 is a negative regulator of chronic liver injury Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function Upregulation of the ACE2/Ang(1-7)/Mas receptor axis in the bile duct ligation (BDL) model of hepatic fibrosis does not affect hepatic sinusoidal resistance Hepatic conversion of angiotensin I and the portal hypertensive response to angiotensin II in normal and regenerating liver Angiotensin-(1-7)-stimulated nitric oxide and superoxide release from endothelial cells Vascular endothelial dysfunction in cirrhosis Influence of caveolin on constitutively activated recombinant eNOS: insights into eNOS dysfunction in BDL rat liver Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition Gradual reactivation of vascular angiotensin I to angiotensin II conversion during chronic ACE inhibitor therapy in patients with diabetes mellitus Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Expression of angiotensin II type 1 receptor in human cirrhotic livers: Its relation to fibrosis and portal hypertension Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors Divergent regulation of circulating and intrarenal renin-angiotensin systems in response to long-term blockade Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2 Angiotensin-(1-7) contributes to the antihypertensive effects of blockade of the renin-angiotensin system The role of Ang (1-7) in mediating the chronic hypotensive effects of losartan in normal rats Vasodepressor actions of angiotensin-(1-7) unmasked during combined treatment with lisinopril and losartan Evidence that prostaglandins mediate the antihypertensive actions of angiotensin-(1-7) during chronic blockade of the renin-angiotensin system Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors Pharmacological effects of AVE 0991, a nonpeptide angiotensin-(1-7) receptor agonist Angiotensin-converting enzyme 2 and new insights into the renin-angiotensin system Dr John Lubel is a recipient of an Australia National Health and Medical Research Council (NHMRC) scholarship, and Peter Angus and Louise Burrell hold an NHMRC project grant (509315). The regulatory role of AT 1 receptor on activated HSCs in hepatic fibrogenesis: effects of RAS inhibitors on hepatic fibrosis induced by CCl(4) Inhibition of renin-angiotensin system attenuates liver enzyme-altered preneoplastic lesions and fibrosis development in rats Effect of losartan, an angiotensin II antagonist, on secondary biliary cirrhosis Effect of losartan on early liver fibrosis development in a rat model of nonalcoholic steatohepatitis Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis Effects of six months losartan administration on liver fibrosis in chronic hepatitis C patients: a pilot study AT1 receptor antagonist Candesartan in selected cirrhotic patients: effect on portal pressure and liver fibrosis markers Effect of angiotensin receptor antagonist on liver fibrosis in early stages of chronic hepatitis C Combined effect of an ACE inhibitor, perindopril, and interferon on liver fibrosis markers in patients with chronic hepatitis C Beneficial effect of angiotensin-blocking agents on graft fibrosis in hepatitis C recurrence after liver transplantation Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis Development, structure and function of the liver Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis Angiotensin II induces contraction and proliferation of human hepatic stellate cells Upregulation of hepatic angiotensin-converting enzyme 2 (ACE2) and angiotensin-(1-7) levels in experimental biliary fibrosis Vasoactive agents in intrahepatic portal hypertension and fibrogenesis: implications for therapy Differential response of normal and cirrhotic liver to vasoactive agents.	cache/cord-311099-59pnm4fn.txt	txt/cord-311099-59pnm4fn.txt
